Updated clinical practice guidelines from the ESMO Guidelines Committee establish structured therapeutic algorithms for metastatic colorectal cancer. Co-authored by Michel Ducreux of Gustave Roussy, the framework standardizes evidence-based care across diverse clinical scenarios, integrating molecular biomarkers and targeted therapies.
Refined Molecular Framework for Metastatic Colorectal Cancer
Managing metastatic colorectal cancer requires navigating an increasingly complex landscape of molecular biomarkers, targeted therapies, and evolving locoregional strategies. Standardizing evidence-based care across diverse clinical scenarios remains essential to optimize patient outcomes. Published in Annals of Oncology on behalf of the ESMO Guidelines Committee, the updated guideline co-authored by Michel Ducreux establishes structured therapeutic algorithms driven by MMR/MSI status, ECOG performance status, primary tumour location, and extended molecular profiling including RAS, BRAF, HER2, and KRAS G12C.
Key updates in the guidance introduce specific pathways for challenging clinical subtypes. These include first-line FOLFOX-encorafenib-cetuximab for BRAF V600E-mutated tumours, ctDNA-guided anti-EGFR rechallenge in the refractory setting, and liver transplantation as a curative-intent option for highly selected patients with unresectable liver-limited disease. By clarifying decision-making criteria from first-line to late-line therapy and across locoregional interventions, the recommendations provide a reference framework for clinical practice in mCRC.
Gustave Roussy Research shared on LinkedIn that the updated ESMO Clinical Practice Guidelines deliver a refined framework for the multidisciplinary management of metastatic colorectal cancer. Cremolini, M. Chalabi, E. Elez, M. Fassan, M. Gelli, D. Goéré, D.P. Modest, C. Montagut, P. Osterlund, J. Ricke, J. Seligmann, J. Taieb, T. Yoshino, L. Wyrwicz, and M. Ducreux.
National Guidance and Regional Procurement Frameworks
Complementing international recommendations, health authorities maintain structured guidance for systemic treatments, including evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Last reviewed on 25 February 2026, this guidance updates and replaces NICE’s technology appraisal guidance 212 on bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer. It also partially updates NICE’s technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118).
Future reviews of this guidance will occur if there is new evidence that is likely to change the recommendations. Commercial arrangements shape the implementation of these therapies across healthcare providers. Regionally available price reductions for bevacizumab (originator and biosimilars) are in place with the Medicines Procurement and Supply Chain, and the prices agreed through the framework are commercial in confidence.
When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations is at the discretion of health professionals and their individual patients, and does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Furthermore, commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.
Multidisciplinary Management and Treatment Algorithms
Clinical decision-making relies on structured algorithms addressing various disease presentations. Detailed flowcharts outline algorithms for the management of metastatic colorectal cancer covering resectable metastatic disease, metastatic disease in the first-line setting, and subsequent lines of therapy.
These algorithms incorporate numerous clinical variables and treatment modalities, referencing 5-fluorouracil (5-FU), aflibercept (Aflib), bevacizumab (Bev), capecitabine (Cape), cetuximab (Cet), chemotherapy (CT), epidermal growth factor receptor (EGFR), 5-fluorouracil+lederfolin+irinotecan (FOLFIRI), folinic acid, 5-FU and irinotecan (FOLFIRI), folinic acid, 5-FU and oxaliplatin (FOLFOX), lederfolin (LV), mutant (mut), progressive disease (PD), performance status (PS), patients (pts), radiotherapy (RT), wild type (wt), and capecitabine+oxaliplatin (XELOX).
Related reading
